Partner with Destina Genomics
License the revolutionary Destina Chemistry and offer PCR-Free nucleic acid biomarker assays on immunoassay platforms.
The Service Lab Bottleneck
Offering nucleic acid diagnostics, especially miRNA assays, is complex and expensive. Separate protein and nucleic acid workflows require different equipment, labs, and SOPs, while PCR-based methods rely on costly reagents and dedicated clean-room environments to control contamination, significantly increasing operational cost and risk.
Complex, Separate Workflows
Running a protein immunoassay and a nucleic acid assay requires different equipment, labs, and SOPs, splitting samples and doubling the work.
High Cost & Contamination Risk
PCR-based methods require expensive reagents (enzymes, polymerases) and dedicated clean-room facilities to prevent contamination, increasing overhead and risk.
The Destina Chemistry Advantage
Our PCR-Free Destina Chemistry allows for the direct detection of nucleic acids with the same simple workflow as a protein immunoassay.
Explore the strategic advantages and core benefits of our hardware-agnostic technology.
Get Started with Destina Chemistry
We are seeking strategic partners to deploy our validated technology. Stop competing on standard assays and start offering exclusive, high-value diagnostics.
License Destina Chemistry for Your Platform
Integrate our Destina Chemistry into your proprietary assay platform. Create novel, PCR-Free assays that your competitors cannot replicate.
Best for: Diagnostic platform companies.
Co-Develop Novel IVD Assays
Do you have a proprietary biomarker (miRNA or protein) and need a robust, multiplex-capable platform? Partner with us to co-develop the next generation of IVD and Companion Diagnostics (CDx).
Best for: Pharma, Biotech, and R&D institutions with novel IP.
A De-Risked, Platform-Agnostic Technology
"Our Destina Chemistry is platform-agnostic by design, enabling seamless adoption on standard immunoassay platforms."
Validated on established multiplex bead-based platforms.
Fully compatible with standard micro-plate readers.
Let's Change the Future of Nucleic Acid Diagnostics
Contact Destina today to discuss licensing or partnership opportunities and gain a definitive competitive advantage in the biomarker market.
Schedule a Partnership Call